Table 1 Socio-demographic and clinical characteristics ( n = 681)
From: Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease
Variable | Â |
|---|---|
Female sex | 423 (62%) |
APOE ε4 carrier, (n = 667) | 437 (66%) |
Solitary living at baseline | 240 (35%) |
Antihypertensives/cardiac therapy | 289 (42%) |
Antidiabetics | 30 (4%) |
Lipid-lowering agents | 63 (9%) |
Estrogens | 51 (7%) |
NSAIDs/acetylsalicylic acid | 212 (31%) |
Antidepressants | 174 (26%) |
Antipsychotics | 30 (4%) |
Anxiolytics/sedatives/hypnotics | 92 (14%) |
Variable | Mean ± standard deviation |
Estimated age at onset (years) | 73.0 ± 6.9 |
Estimated duration of AD at baseline (years) | 3.1 ± 2.0 |
Age at first assessment (years) | 76.1 ± 6.5 |
Education (years) | 9.3 ± 2.4 |
Age at death (years) | 81.9 ± 6.6 |
MMSE score at baseline | 20.9 ± 3.9 |
ADAS-cog score (0-70) at baseline | 22.0 ± 9.1 |
IADL score at baseline | 16.6 ± 5.4 |
PSMS score at baseline | 7.7 ± 2.3 |
Number of concomitant medications at baseline | 3.0 ± 2.5 |